Core Viewpoint - The article emphasizes the role of state-owned capital in venture capital, highlighting the balance between adhering to national strategic missions and achieving efficient market-based resource allocation through the example of Jianfa Emerging Investment [1][3]. Group 1: Company Overview - Jianfa Emerging Investment, a professional equity asset management institution under Jianfa Group, has collaborated with over 70 GP institutions and managed funds exceeding 29 billion yuan, achieving a net profit of over 4 billion yuan since its establishment [3][4]. - The investment focus includes new economic sectors such as healthcare, advanced manufacturing, and TMT/consumption, with notable investments in companies like CATL, Huaxi Bio, and ZhiPu AI [3][4]. Group 2: Strategic Role - The company acts as a bridge and translator between government strategic directives and market innovation, converting policy language into specific investment standards and risk control requirements [4][5]. - Jianfa Emerging Investment's operations are supported by the Xiamen municipal government, allowing it to leverage market advantages while serving national and regional development goals [3][4]. Group 3: Investment Philosophy - The company advocates for a market-oriented approach, encouraging more state-owned LPs to release capital for market-based allocations to foster a healthy venture capital ecosystem [5][6]. - Jianfa Emerging Investment is committed to supporting new funds and emerging GPs, emphasizing a willingness to invest in smaller GP institutions and nurturing new talent in the industry [5][6]. Group 4: Innovation and Culture - The company promotes a culture of innovation, encouraging employees to take risks and explore new opportunities without the fear of accountability, reflecting the entrepreneurial spirit of its Fujian roots [6]. - The leadership believes in actively pushing boundaries and embracing new challenges, aligning with the broader ethos of technological innovation and market exploration [6].

Core Viewpoint - The article emphasizes the role of state-owned capital in venture capital, highlighting the balance between government direction and market execution, as exemplified by Jianfa Emerging Investment's approach to investment [1][2]. Group 1: Company Overview - Jianfa Emerging Investment has been operational for ten years, collaborating with over 70 GP institutions and managing more than 29 billion yuan, achieving a net profit exceeding 4 billion yuan [2]. - The investment focus includes sectors such as healthcare, advanced manufacturing, and TMT/consumption, with notable investments in companies like CATL, Huaxi Bio, and others [2]. Group 2: Investment Strategy - The company positions itself as a bridge and translator between government strategies and market innovations, converting policy language into specific investment standards [3]. - Jianfa Emerging Investment advocates for a more market-oriented approach among state-owned LPs, encouraging the release of more capital for market-driven investments [4]. Group 3: Support for New GPs - The company is committed to supporting new GPs and is willing to invest in smaller institutions, emphasizing the importance of nurturing emerging talent in the investment landscape [4]. - Jianfa Emerging Investment employs a quantitative scoring system for selecting GPs, focusing on open communication and cognitive alignment [4]. Group 4: Innovation and Risk-Taking - The company encourages a culture of innovation and risk-taking, allowing employees to experiment without fear of repercussions, reflecting the entrepreneurial spirit of its Fujian roots [6]. - Jianfa Emerging Investment believes in actively pushing boundaries and embracing new challenges, embodying the "love to win" mentality characteristic of the region [6].

Core Viewpoint - The article emphasizes the role of Jianfa Emerging Investment as a state-owned capital investment institution that effectively bridges government strategies and market innovation through market-oriented operations [1][2]. Group 1: Company Overview - Jianfa Emerging Investment has been operational for ten years, collaborating with over 70 GP institutions and managing funds exceeding 29 billion yuan, achieving a net profit of over 4 billion yuan since its inception [1]. - The investment focus includes sectors such as healthcare, advanced manufacturing, and TMT/consumption, with notable investments in companies like CATL, Huaxi Bio, and ZhiPu AI [1]. Group 2: Strategic Role - The company positions itself as a "bridge" and "translator" between government strategies and market dynamics, converting policy language into specific investment standards and risk control requirements [2]. - It aims to facilitate the alignment of entrepreneurial ventures with local government resources, thereby enhancing the effectiveness of both government and market operations [2]. Group 3: Support for New GP - Jianfa Emerging Investment is committed to supporting new funds and emerging GPs, advocating for the gradual "decontrol" of state-owned capital to enhance market-oriented investment capabilities [3]. - The company employs a quantitative scoring system for selecting GPs, focusing on open communication and cognitive alignment [3]. Group 4: Innovation Approach - The company encourages a proactive approach to innovation, promoting a culture where employees are motivated to experiment and take calculated risks without fear of repercussions [4]. - Jianfa Emerging Investment embodies the entrepreneurial spirit of its Fujian roots, emphasizing the importance of stepping out of comfort zones to embrace new challenges [4].

Investment Rating - The report initiates coverage with a "Buy" rating for Shuiyang Co., Ltd. [3][13] Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index increasing by 0.2% from September 5 to September 12, 2025, lagging behind the Shenwan A Index by 2.7 percentage points [3][4] - Domestic cosmetics brands showed strong growth in August, with key brands under Shumei Co. achieving a 70% growth rate on Douyin and Taobao platforms, indicating a robust performance despite high base effects [3][9] - The report highlights the upcoming Double 11 shopping festival, suggesting that brands should prepare for promotional strategies [3][9] Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with declines in the Shenwan Cosmetics Index by 0.5% and the Shenwan Personal Care Index by 0.8% during the specified period [3][4] Key Company Review - Shuiyang Co., Ltd. is positioned as a leading technology-driven beauty company in China, with stable revenue between 4 to 5 billion yuan from 2021 to 2024 and an expected gross margin of 63.01% in 2024, up by 10.94 percentage points from 2021 [3][10] - The company has a dual business model of proprietary brands and CP agency brands, with a strong focus on high-end and global market transformation [3][10][12] E-commerce Data - In August, key domestic brands on Douyin and Taobao platforms showed significant growth, with Shumei Co. brands achieving a 70% increase, and other brands like Maogeping and Runben also reporting substantial growth rates [3][14] Market Trends - The report notes that the overall retail sales of cosmetics in July 2025 grew by 4.5%, indicating a recovery in consumer spending [3][17] - The domestic skincare market is projected to reach 271.2 billion yuan in 2024, despite a slight decline of 3.7% year-on-year, with domestic brands gaining market share [3][26] Company Announcements - Shumei Co. has appointed Dr. Karl Lintner, a pioneer in peptide beauty, as the chief scientific advisor, aiming to enhance its global competitiveness in research and development [3][21]

Investment Rating - The report maintains a "Positive" investment rating for the cosmetics industry [3] Core Insights - The cosmetics industry is experiencing stable growth with a slight improvement in growth rates, while profitability continues to show differentiation among companies [11][16] - The average revenue growth rate for the cosmetics industry in Q1 and Q2 of 2025 was -8.4% and -2.1%, respectively, indicating a slight improvement in the second quarter [16] - Online sales channels, particularly Tmall and Douyin, have shown a year-on-year growth of 13.1% in the first half of 2025, reflecting a recovery in consumer demand [11] Summary by Sections Cosmetics: Stable Growth and Business Adjustments - The cosmetics industry showed a year-on-year growth of 3.1% and 2.6% in Q1 and Q2 of 2025, respectively, with a significant improvement compared to the -1.1% growth in 2024 [11] - The industry is characterized by a slight improvement in growth rates, with the overall growth falling into a stable range [11] Revenue: Differentiation Among Brands - The average revenue growth for the brand segment was 0.4% and 6.5% in Q1 and Q2 of 2025, respectively, indicating stronger resilience compared to upstream and downstream segments [16] - Mid-sized brands like Maogeping and Shangmei have achieved good growth amidst a stable industry backdrop, while leading companies like Proya continue to grow steadily [16] Gross Margin Trends - The average gross margin for the brand segment increased by 1.6 percentage points in the first half of 2025, driven by improved business structures and effective price control by certain brands [21] - Specific brands like Water Sheep and Beitaini have seen significant improvements in gross margins due to product upgrades and price management strategies [21] Product Innovation: Focus on Core Series and Efficacy Expansion - Brands are focusing on upgrading core product lines and expanding efficacy categories, particularly in sunscreen and whitening, with increased competition expected [25] - New product launches include Proya's whitening series and Beitaini's anti-aging products, indicating a trend towards enhancing product offerings [25] Sales Expenses: Rising Industry Rates - The average sales expense ratio for brands in the first half of 2025 was 44.7%, reflecting a year-on-year increase of 1.7 percentage points, influenced by rising competition and platform costs [31] - The narrowing of gross sales margins indicates ongoing pressure on profitability across the industry [31]

Investment Dynamics - Nutrabolt, an American energy drink company, has invested nearly 110 million yuan to increase its stake in Bloom Nutrition [4] - Bloom Nutrition, founded in 2019, is well-known on social media for its organic green superfood powders and has expanded its product line to include protein powders, collagen peptides, and super berry products [2] - This investment is expected to provide Bloom Nutrition with strategic growth capital, enhance its production capacity, and strengthen its internal capabilities, while allowing Nutrabolt to further expand its influence in the energy drink sector [2] Brand Dynamics - Inditex Group, the parent company of Zara, reported a 5.1% year-on-year revenue growth to 18.4 billion euros and a slight net profit increase of 0.8% to 2.8 billion euros as of July 31 [15] - Zara is closing smaller stores and shifting towards larger, higher-end retail spaces, with an expected total retail floor area increase of about 5% in the coming year [15] - The closure of smaller stores reflects a broader trend in the fast fashion industry, prioritizing efficiency over scale [15] Corporate Changes - Roberto Lorenzini announced his resignation as CEO of Tod's Group for the Americas, a decision made in agreement with the Della Valle family [23] - Sun Hui, CEO of Baizicui, announced her departure after seven years, indicating challenges in achieving rapid success in a competitive environment [26] - Burger King China appointed Fan Jun as COO and Li Jia as CIO, aiming to strengthen its core team for better market penetration [28]

Market Overview - The Shanghai Composite Index fell by 0.12% on September 12, with 9 out of the 28 sectors rising, led by non-ferrous metals and real estate, which increased by 1.96% and 1.51% respectively [1] - The communication and comprehensive sectors experienced the largest declines, down by 2.13% and 1.95% respectively [1] - Overall, there was a net outflow of 53.64 billion yuan in the main funds across the two markets, with 6 sectors seeing net inflows [1] Sector Performance - The non-ferrous metals sector had the highest net inflow of main funds, totaling 2.168 billion yuan, coinciding with its 1.96% increase [1] - The construction and decoration sector also saw a positive performance with a 0.96% rise and a net inflow of 721 million yuan [1] - In contrast, the non-bank financial sector had the largest net outflow, amounting to 8.138 billion yuan, followed by the electronics sector with a net outflow of 7.517 billion yuan [1] Beauty and Personal Care Industry - The beauty and personal care sector declined by 1.52% with a net outflow of 228 million yuan [2] - Out of 29 stocks in this sector, 5 rose while 24 fell [2] - The top three stocks with the highest net outflows included Aimeike, Shanghai Jahwa, and Proya, with outflows of 55.4558 million yuan, 51.6741 million yuan, and 38.7707 million yuan respectively [2][3] Fund Flow in Beauty and Personal Care - The top stock in terms of net inflow was Shuiyang Co., with an inflow of 12.3562 million yuan, followed by Zhongshun Jierou and Huaxi Biological, with inflows of 10.1629 million yuan and 7.6373 million yuan respectively [2][4] - The table of fund flow indicates that Aimeike had the largest outflow at -55.4558 million yuan, with a decline of 3.03% [3] - Other notable outflows included Shanghai Jahwa at -51.6741 million yuan and Proya at -38.7707 million yuan [3]

当前，国资LP和政府投资基金已经成为创投市场的出资主力军。但大量国资LP和政府投资基金是从国家战略发展、地方产业升级等角度考虑，通常都带有 一定的返投要求。 "我们呼吁有更多市场化运作国资LP出现，这将利于创投行业生态的长期健康发展。"近日，建发新兴投资董事长王文怀在接受21世纪经济报道记者采访时 说。 据了解，建发新兴投资成立于2014年12月，是厦门建发集团旗下的新兴产业投资平台。同时，它也是一家建立在服务国家高质量发展和厦门市经济社会发展 基础上，充分发挥市场化运作优势的国有资本机构。 经过十多年发展，建发新兴投资的管理资金规模超过290亿元。其参与投资基金超120只，合作的GP包括启明创投、礼来亚洲基金、龙磐投资、君联资本、 钟鼎资本、黑蚁资本等。同时，其参与企业投资超220家，项目覆盖医疗健康、先进制造、TMT/消费领域，包括康龙化成（300759）、华熙生物、澜起科 技、惠泰医疗、中伟股份（300919）等。 值得注意的是，建发新兴投资虽然是地方政府支持下、地方国有企业培育出来的LP机构，但主要通过市场化方式在一级市场进行多样化资产配置。 "我们非常关注国家高质量发展带来的产业发展机遇，然后通过市 ...

Core Insights - The skincare and daily chemical industry in A-share listed companies has shown improvement in inventory status as of the first half of 2025, with only 6 out of 14 selected companies experiencing an increase in inventory scale [1] - Among the selected companies, only 5 have inventory turnover days below 90 days, indicating potential inefficiencies in inventory management for the remaining 9 companies [1] - The inventory turnover efficiency indicators for the industry are concerning, with 6 companies showing prolonged inventory turnover days, which may suggest risks of product obsolescence or slow sales [1] Inventory Analysis - In the first half of 2025, the inventory situation improved for the skincare and daily chemical listed companies, with a notable increase in inventory scale for Jinbo Biological, which had the highest year-on-year growth [1] - Only 5 companies, including Jiaheng Home, Qingsong Co., Proya, Shanghai Jahwa, and Lafang, maintained inventory turnover days below 90, while the other 9 exceeded this threshold [1] - Companies such as Huaxi Biological and Jinbo Biological are among those with longer inventory turnover days, raising concerns about their inventory management practices [1] Market Implications - The prolonged inventory turnover days across several companies may indicate a longer time frame from production to sale, potentially leading to product expiration risks [1] - The overall inventory turnover efficiency in the skincare and daily chemical sector is not optimistic, highlighting a need for companies to improve their inventory management strategies [1]

Core Insights - The skincare and daily chemical industry in A-share listed companies has shown improvements in inventory levels as of the first half of 2025, with only 6 out of 14 selected companies experiencing an increase in inventory size [1][2] Inventory Size Analysis - Jinbo Biological had the largest year-on-year increase in inventory, reaching 153 million yuan, a growth of 116.79% compared to the first half of 2024 [1][2] - Kesheng Co. also saw significant growth, with inventory at 628 million yuan, up 40.87% year-on-year [1][2] - Other companies with notable inventory increases include Marubi Biological (35.91%), Chuang'er Biological (34.02%), and Jiaheng Home Care (31.39%) [2] Inventory Turnover Days - Among the 14 selected companies, only 5 had inventory turnover days below 90 days, indicating efficient inventory management [3] - Companies with inventory turnover days exceeding 180 days include Huaxi Biological (331.61 days), Jinbo Biological (280.81 days), Kesheng Co. (230.92 days), and Betaini (195.78 days) [3][4] - The overall inventory turnover efficiency has not improved, with 8 companies experiencing longer turnover days, particularly those exceeding 180 days [3] Year-on-Year Changes in Inventory Turnover Days - Huaxi Biological's turnover days increased by 13.34%, Jinbo Biological by 15.66%, Kesheng Co. by 115.83%, and Betaini by 0.54% [3][4] - Notably, the turnover days for LaFang Home Care decreased by 27.40%, and Shanghai Home Care by 15.74%, indicating some companies are managing their inventory more effectively [4]